糖尿病肾脏疾病药物治疗研究进展  

Progress in pharmacotherapy of diabetic kidney disease

作　　者：陈威宇 唐子勇[2] 毕书红[2] CHEN Wei-yu;TANG Zi-yong;BI Shu-hong(Department of Internal Medicine,Pelhing University Third Hospital,Beijing 100191,China;Department of Nehprology,Pelhing University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院临床医学内科学系,北京100191 [2]北京大学第三医院肾内科,北京100191

出　　处：《临床药物治疗杂志》2019年第12期10-14,共5页Clinical Medication Journal

摘　　要：糖尿病肾脏疾病(diabetic kidney disease,DKD)是由糖尿病所致的慢性肾脏疾病(chronic kidney disease,CKD),是终末期肾脏疾病的重要病因。目前DKD的治疗主要包括生活方式改变,加强血压、血糖控制,减少蛋白尿,预防心脑血管并发症以及终末期的肾脏替代治疗等。糖尿病肾脏疾病仍存在患病率高,缺乏有效延缓肾脏病进展手段等问题。近年来,随着对DKD发病机制研究的深入,新型降糖药物、肾素-血管紧张素-醛固酮系统(reninangiotensin-aldosterone system,RAAS)抑制剂以及针对糖尿病肾脏疾病发病机制的药物,为DKD的药物治疗提供了新的选择。本文从DKD的病理及发病机制出发,重点综述了DKD的药物治疗进展。Diabetic kidney disease(DKD) is a chronic kidney disease(CKD) caused by diabetes and major cause of the end stage renal disease.Therapy of diabetic kidney disease includes lifestyle change,ehanced blood pressure and blood glucose control,reducing albuminuria,preventing cardiovascular and cerebrovascular complication,and replacement therapy in end stage renal disease.There are still some problems in diabetic nephropathy,such as high prevalence and lack of effective measures to delay the progression of kidney disease.In recent years,with the development of research on the pathogenesis of DKD,new hypoglycemic agent,renin-angiotensin-aldosterone system(RAAS) inhibitor and durgs targeting topathogenesis of DKD provide more choice in pharmacotherapy of DKD.Based on the pathology and pathogenesis of DKD,this article reviews the progress of drug treatment of DKD.

关 键 词：糖尿病肾脏疾病 药物治疗 糖代谢 肾素-血管紧张素-醛固酮系统阻滞剂 内皮素受体拮抗剂 

分 类 号：R692[医药卫生—泌尿科学]